<DOC>
	<DOC>NCT00692510</DOC>
	<brief_summary>The purpose of the study is to evaluate if AZD3480 inhibits Cytochrome P450 1A2, 2C19, 3A4, 2C8, 2B6 and UGT1A1 activity.</brief_summary>
	<brief_title>Drug Interaction Study Between AZD3480 and Cytochrome P450</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Rosiglitazone</mesh_term>
	<mesh_term>Omeprazole</mesh_term>
	<mesh_term>Caffeine</mesh_term>
	<mesh_term>Bupropion</mesh_term>
	<mesh_term>Midazolam</mesh_term>
	<mesh_term>Bilirubin</mesh_term>
	<criteria>Provision of signed written informed consent Clinically normal physical findings and laboratory values Clinically significant illness or clinically relevant trauma within three weeks before the first dose History of clinically significant disease Use of prescribed medication during the 2 weeks before administration of the first dose of investigational product</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>November 2008</verification_date>
	<keyword>AZD3480</keyword>
	<keyword>Cocktail</keyword>
	<keyword>caffeine</keyword>
	<keyword>bupropion</keyword>
	<keyword>omeprazole</keyword>
	<keyword>midazolam</keyword>
	<keyword>rosiglitazone</keyword>
	<keyword>metabolism</keyword>
	<keyword>Drug Drug Interaction</keyword>
</DOC>